Clinical trial
PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk.
NCT02970604 is registered in ClinicalTrials.gov with Royal College of Surgeons, Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk.
- Lead sponsor
- Royal College of Surgeons, Ireland
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- May 31, 2016
- Completion date
- February 28, 2018
- Enrollment
- 160 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.